- Home
- MFIN vs NTHI Comparison
MFIN vs NTHI Comparison
Compare MFIN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | NTHI |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 195.5M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MFIN | NTHI |
|---|---|---|
| Price | $10.65 | $10.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 43.3K | ★ 68.0K |
| Earning Date | 10-29-2025 | 11-14-2025 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $6.12 | ★ N/A |
| Revenue Growth | ★ 15.53 | N/A |
| 52 Week Low | $7.71 | $3.20 |
| 52 Week High | $10.98 | $25.00 |
Technical Indicators
Market Signals| Indicator | MFIN | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 58.54 |
| Support Level | $9.96 | $8.63 |
| Resistance Level | $10.39 | $9.75 |
| Average True Range (ATR) | 0.31 | 0.88 |
| MACD | 0.08 | 0.23 |
| Stochastic Oscillator | 87.87 | 95.59 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).